Medication adherence among men who have sex with men at risk for HIV infection in the United States: Implications for pre-exposure prophylaxis implementation

AIDS Patient Care and STDs

Volumn 28, Issue 12, 2014, Pages 622-627

  Liu, Albert Y ^a,b   Hessol, Nancy A ^b,c   Vittinghoff, Eric ^b   Rivet Amico, K ^d   Kroboth, Elizabeth ^a   Fuchs, Jonathan ^a,b   Irvin, Risha ^e   Craig Sineath, R ^f   Sanchez, Travis ^f   Sullivan, Patrick S ^f   Buchbinder, Susan P ^a,b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG COST; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; PATIENT COMPLIANCE; SELF CONCEPT; SELF MEDICATION; SEXUAL PRACTICE; UNITED STATES; ADOLESCENT; ATTITUDE TO HEALTH; FEMALE; HEALTH SURVEY; HIV INFECTIONS; MALE HOMOSEXUALITY; MIDDLE AGED; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; PSYCHOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNSAFE SEX; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRE-EXPOSURE PROPHYLAXIS; RISK FACTORS; UNITED STATES; UNSAFE SEX; YOUNG ADULT;

EID: 84918795503     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2014.0195     Document Type: Article

References (38)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-434.
4. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090.
5. U.S. Food and Drug Administration. Truvada for PrEP Fact Sheet: Ensuring Safe and Proper Use: U.S. Department of Health and Human Services, 16 July 2012.
6. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: Where have we been and where are we going? J Acquir Immune Defic Syndr 2013;63:S122-S129.
7. Centers for Disease Control and Prevention. Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011;60:65-68.
8. Center for Disease Control. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States-2014 Clinical Practice Guideline: US Public Health Service, 2014.
9. Center for Disease Control. HIV Surveillance Report, 2011. Atlanta: Centers for Disease Control and Prevention, 2013.
10. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502.
11. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-422.
12. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: Implications for HIV prevention in women. Lancet 2011;378:279-281.
13. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4:151ra125.
14. Microbicides Trial Network. Microbides Trial Network (MTN) statement on decision to discontinue use of tenofovir gel in VOICE, major prevention study in women. Pittsburgh, PA 25 November 2011.
15. Amico KR. Adherence to preexposure chemoprophylaxis: The behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS 2012;7:542-548.
16. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: Facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS 2013;27:248-254.
17. Gilmore HJ, Liu A, Koester KA, et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDS 2013;27:560-566.
18. DeSevo G, Klootwyk J. Pharmacologic issues in management of chronic disease. Prim Care 2012;39:345-362.
19. Volk JE, Liu A, Vittinghoff E, et al. Sexual frequency and planning among at-risk men who have sex with men in the United States: Implications for event-based intermittent pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2012;61:112-115.
20. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav 2008;12:86-94.
21. Stata. Stata Statistical Software:Version 12.1. College Station, TX: Stata Corporation, 2012.
22. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother 2000;34: 703-709.
23. Gray J. Becoming adherent: Experiences of persons living with HIV/AIDS. J Assoc Nurses AIDS Care 2006;17: 47-54.
24. Demonceau J, Ruppar T, Kristanto P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: A systematic literature review and meta-analysis. Drugs 2013;73:545-562.
25. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Co-chrane Database Syst Rev 2008:CD000011.
26. Lindsey JC, Bosch RJ, Rudy BJ, Flynn PM. Early patterns of adherence in adolescents initiating highly active anti-retroviral therapy predict long-term adherence, virologic, and immunologic control. AIDS Patient Care STDS 2009; 23:799-801.
27. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: A study of prevalence and interactions. AIDS Patient Care STDS 2009;23:185-194.
28. Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005;159:764-770.
29. Beer L, Heffelfinger J, Frazier E, et al. Use of and adherence to antiretroviral therapy in a large U.S. sample of HIV-infected adults in care, 2007-2008. Open AIDS J 2012;6:213-223.
30. Branas F, Berenguer J, Sanchez-Conde M, et al. The eldest of older adults living with HIV: Response and adherence to highly active antiretroviral therapy. Am J Med 2008;121: 820-824.
31. Anderson P, Lama JR, Buchbinder S, et al. Interpreting Detection Rates of Intracellular FTC-TP and TFV-DP: The iPrEx Trial. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 27-March 2, 2011:Abst # 96LB
32. Hosek SG, Siberry G, Bell M, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr 2013;62:447-456.
33. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). Paper presented at: 20th Conference on Retroviruses and Opportunitic Infections. Atlanta, GA; March 3-6, 2013:Abst. #26LB.
34. Bekker LG, Glidden DV, Hosek S, et al. Pre-exposure Prophylaxis in Young Men Who Have Sex with Men: Needs and Challenges. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia; March 3-6, 2013:Abst. #997.
35. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: Experiences, insights and future directions from four multisite prevention trials. AIDS Behav 2013;17:2143-2155.
36. Amico KR, McMahan V, Marcus J, et al. Integrated Next Step Counseling (iNSC): A discussion based sexual health promotion conversation to support men who have sex with men using PrEP in the iPrEx open label extension. Paper presented at: 7th International Conference on HIV Treatment and Prevention Adherence. Miami, FL; June 3-5 2012:Abst. #80467.
37. Vital signs: HIV testing and diagnosis among adults-United States, 2001-2009. MMWR Morb Mortal Wkly Rep 2010;59:1550-1555.
38. Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr 2012;61:490-498.